Genmab Share Price Cinnober Boat
Stocks
0MGB
DK0010272202
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 119B 18.37B 15.92B 14.9B 13.6B 25.59B 1,752B 26.02B 175B 68.46B 877B 68.96B 67.46B 2,925B | P/E 2026 * |
25.2x | P/E 2027 * | 17.8x |
|---|---|---|---|---|---|
| Enterprise Value | 139B 21.4B 18.55B 17.36B 15.84B 29.81B 2,041B 30.31B 204B 79.76B 1,022B 80.36B 78.6B 3,409B | EV / Sales 2026 * |
4.78x | EV / Sales 2027 * | 3.87x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 31/05/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 29/02/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 15/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 31/10/2003 | |
| Director/Board Member | 58 | 31/12/2014 | |
| Director/Board Member | 75 | 31/12/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 18.37B | |
| -0.70% | +13.34% | +75.61% | +103.83% | 70.85B | |
| -2.35% | +2.88% | +35.39% | +64.72% | 55.41B | |
| -1.62% | +34.25% | +17.43% | +491.04% | 29.43B | |
| -1.39% | +11.72% | +53.52% | +6.65% | 24.12B | |
| 0.00% | +1.59% | -15.06% | -13.21% | 23.31B | |
| +0.05% | +6.12% | +46.81% | -21.81% | 18.37B | |
| +9.77% | +20.16% | +260.17% | +472.38% | 16.99B | |
| +0.28% | +7.77% | +31.32% | +626.03% | 16.1B | |
| -3.08% | -8.34% | +37.21% | +138.52% | 13.12B | |
| Average | +0.10% | +391.85% | +60.27% | +207.57% | 29.75B | |
| Weighted average by Cap. | -0.45% | +350.76% | +56.20% | +167.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.99B 4.48B 3.88B 3.63B 3.31B 6.23B 427B 6.34B 42.57B 16.68B 214B 16.8B 16.44B 713B | 33.66B 5.2B 4.5B 4.22B 3.85B 7.24B 496B 7.36B 49.43B 19.37B 248B 19.51B 19.08B 828B |
| Net income | 4.94B 763M 661M 619M 565M 1.06B 72.75B 1.08B 7.26B 2.84B 36.41B 2.86B 2.8B 121B | 7.14B 1.1B 955M 894M 815M 1.53B 105B 1.56B 10.48B 4.11B 52.59B 4.14B 4.05B 175B |
| Net Debt | 19.66B 3.03B 2.63B 2.46B 2.25B 4.23B 289B 4.3B 28.86B 11.31B 145B 11.39B 11.14B 483B | 11.22B 1.73B 1.5B 1.41B 1.28B 2.41B 165B 2.45B 16.48B 6.46B 82.71B 6.51B 6.36B 276B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
